Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.69 |
| ▸ | PDGFRA | P16234 | 18/20 | 0.69 |
| ▸ | KIT | P10721 | 3/20 | 0.60 |
| ▸ | AXL | P30530 | 2/20 | 0.60 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.60 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.56 |
| ▸ | STK10 | O94804 | 2/20 | 0.56 |
| ▸ | ABL1 | P00519 | 2/20 | 0.56 |
| ▸ | LCK | P06239 | 2/20 | 0.56 |
| ▸ | LYN | P07948 | 2/20 | 0.56 |
| ▸ | RET | P07949 | 2/20 | 0.56 |
| ▸ | MET | P08581 | 2/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.56 |
| ▸ | SRC | P12931 | 2/20 | 0.56 |
| ▸ | FLT1 | P17948 | 2/20 | 0.56 |
| ▸ | FLT4 | P35916 | 2/20 | 0.56 |
| ▸ | FLT3 | P36888 | 2/20 | 0.56 |
| ▸ | ABL2 | P42684 | 2/20 | 0.56 |
| ▸ | FRK | P42685 | 2/20 | 0.56 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670090 | 0.91 | KDR (0.74) | KDRPDGFRAKITAXLFGFR2 | |
| SCHEMBL4668490 | 0.90 | KDR (0.65) | KDRPDGFRAKITAXLFGFR2 | |
| SCHEMBL4668548 | 0.88 | PDGFRA (0.74) | KDRPDGFRA | |
| SCHEMBL4669699 | 0.86 | PDGFRA (0.53) | KDRPDGFRAKITAXLFGFR2 | |
| SCHEMBL4668541 | 0.83 | PDGFRA (0.58) | KDRPDGFRAMETFLT3 | |
| SCHEMBL13627264 | 0.82 | KDR (0.64) | KDRPDGFRAKITAXLFGFR2 | |
| SCHEMBL4668527 | 0.80 | KDR (0.70) | KDRPDGFRAKITAXLFGFR2 | |
| SCHEMBL4669905 | 0.80 | KDR (0.65) | KDRPDGFRAKITAXLFGFR2 | |
| SCHEMBL4668520 | 0.80 | KDR (0.70) | KDRPDGFRAKITAXLFGFR2 | |
| SCHEMBL4669930 | 0.80 | KDR (0.70) | KDRPDGFRAKITAXLFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1652847-B1 | Quinoline and quinazoline derivatives for the treatment of tumors | KIRIN PHARMA KK (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1652847-A1 | Quinoline and quinazoline derivatives for the treatment of tumors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-05-03 | — | — | EP | claimed |
| EP-1652847-B1 | Quinoline and quinazoline derivatives for the treatment of tumors | KIRIN PHARMA KK (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-7211587-B2 | Quinoline derivatives and quinazoline derivatives having azolyl group | KIRIN BEER KABUSHIKI KAISHA (KR) | 2007-05-01 | — | — | US | disclosed |
| EP-1652847-A1 | Quinoline and quinazoline derivatives for the treatment of tumors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-6821987-B2 | 4-SUBSTITUTED BY AZOLYLUREIDO-PHENOXY, OR PHENYLTHIO; ANTITUMOR AGENTS; TREATING DIABETIC RETINOPATHY, CHRONIC RHEUMATISM, PSORIASIS, ATHEROSCLEROSIS, | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-11-23 | — | — | US | disclosed |
| US-20040229876-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-11-18 | — | — | US | disclosed |
| EP-1382604-A1 | QUINOLINE DERIVATIVE HAVING AZOLYL GROUP AND QUINAZOLINE DERIVATIVE | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-20030087907-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | KIRIN BEER KABUSHIKI KAISHA (JP) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229876-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | NQO2, H1-5, NRAS | KDR 3455/4885PDGFRA 4104/4885KIT 2254/4885 |
| US-20030087907-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | NQO2, H1-5, NRAS | KDR 3455/4885PDGFRA 4104/4885KIT 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.